Search

3D porous nano-LiMn2O4 (nano-LMO) is successfully prepared at 250 °C by a low temperature pyrolysis, using porous MnO2 and lithium acetate as reactants. The as-formed porous samples are demonstrated to be constructed by well-defined and uniform cubic nanocrystals with particle sizes regulated from tens to hundreds of nanometers by adjusting the annealing temperature. Due to its proper particle size with perfect crystallization (∼50 nm) and rich pores, sample LMO-265, prepared at 265 °C, exhibits high performance as an aqueous lithium ion cathode. It can present a high specific capacity of 102 mAh g−1 at a current density of 5C with a greatly improved rate capability (57.3%, 68C) and capacity retention (70.7%, after 5000 cycles at 13.5C) in 1 M Li2SO4. When assembled with commercial used active carbon (AC) to form an aqueous hybrid capacitor, it can deliver a high energy density of 15.8 Wh kg−1 at a large power density of 9 kW kg−1 with a good cycling life of 71.6% after 5000 at 2 A g−1. Considering of its simple and economical preparation, as-prepared porous LMO can be regarded as a promising high-performance cathode material in aqueous electrolyte.

Our study investigated the correlation between sarcopenia and clinical outcomes in patients with hepatocellular carcinoma (HCC) treated with lenvatinib. We retrospectively evaluated 40 consecutive patients with unresectable HCC receiving lenvatinib between November 2018 and May 2020 at the First Hospital of Jilin University. Skeletal muscle mass was measured before treatment initiation. Prognostic significance was assessed with univariate and multivariate Cox proportional hazards models. Overall survival (OS) and progression-free survival (PFS) were evaluated for patients with and without sarcopenia. Sarcopenia was present in 23/40 patients (57.5%). After a median follow-up of 9.2 months, patients with sarcopenia had significantly worse OS and PFS compared with those without sarcopenia (OS: 8.4 months [m] vs 14.7 m, P = .02; PFS: 4.2 m vs 9.0 m, P = .04). Multivariate Cox proportional hazards models identified presence of sarcopenia as an independent risk factor for shorter OS (hazard ratio [HR], 0.257; 95% confidence interval [CI], 0.083-0.794; P = .02). In subgroup analysis, sarcopenia was associated with worse survival than non-sarcopenic patients, irrespective of age, Barcelona clinic liver cancer stage, or albumin-bilirubin grade. Our results show sarcopenia may be a predictor of poor prognosis in patients with HCC receiving lenvatinib. Management of sarcopenia is a vital factor for improving survival outcomes in patients with HCC.

Objective: To obtain the pattern and reactivity extent of E-cadherin and correlation with clinicopathological data including tumor type, grade, and lymph node status. Methods: Expression of E-cadherin has been examined in 20 gastric carcinomas; 21 colorectal carcinomas; 20 uterocervical carcinomas and 20 breast carcinomas using an immunohistochemical technique. Results: There were similar patterns among four kinds of cancer. Tumors with a decreased E-cadherin occurred significantly more frequently in poor differentiated carcinomas. There was association between membrane levels of E-cadherin and the presence of lymph node metastasis, but the difference was not significant. Conclusions: E-cadherin expression of the noncancerous areas is higher than that of the cancerous areas. The decreased E-cadherin expression correlates with dedifferentiation. The relation between the E-cadherin expression and the metastasis is complex and need much more research. There are similar patterns among four types of cancer. For that, immunohistochemical study of E-cadherin may have clinicopathologic value for patients with cancer.